Asset
Deflazacort
PTC Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02251600 | phase1 | completed | 2014-12-01 | 2015-10-01 | PTC Therapeutics | A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy |
| NCT02286609 | phase1 | completed | 2014-12-01 | 2015-02-01 | PTC Therapeutics | A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics |
| NCT02286622 | phase1 | completed | 2014-12-01 | 2015-02-01 | PTC Therapeutics | A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics |
| NCT03642145 | phase3 | withdrawn | 2018-10-31 | 2021-07-31 | PTC Therapeutics | A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD) |
| NCT03783923 | phase3 | terminated | 2019-10-31 | 2021-01-01 | PTC Therapeutics | A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 208684 | NDA | PTC THERAPEUTICS INC |
| NDA 208685 | NDA | PTC THERAPEUTICS INC |
Marketed products (5)
- EMFLAZA
- EMFLAZA
- EMFLAZA
- EMFLAZA
- EMFLAZA